(S)-(2-(二甲基氨基)-2-氧代-1-苯基乙基)氨基甲酸苄酯 | 394734-93-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-(2-(二甲基氨基)-2-氧代-1-苯基乙基)氨基甲酸苄酯
• 英文名称: (S)-benzyl 2-(dimethylamino)-2-oxo-1-phenylethylcarbamate
• 英文别名: benzyl [(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]-carbamate；benzyl [(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]carbamate；Benzyl (S)-(2-(dimethylamino)-2-oxo-1-phenylethyl)carbamate；benzyl N-[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]carbamate
• CAS: 394734-93-1
• 化学式: C₁₈H₂₀N₂O₃
• 分子量: 312.368
• InChiKey: NMJWPHNWHMPBOP-INIZCTEOSA-N

物化性质

• 沸点：
  504.8±50.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-(2-(二甲基氨基)-2-氧代-1-苯基乙基)氨基甲酸苄酯 在 lithium aluminium tetrahydride 、 palladium 10% on activated carbon 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 N-(2S)-2-氨基-2-苯基乙基-N,N-二甲胺
  参考文献：
  名称：

  Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors

  摘要：

  The P21-activated kinases (PAK) are emerging antitumor therapeutic targets. In this paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design. In addition, the efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.

  DOI：

  10.1021/jm300204j
• 作为产物：
  描述：

  盐酸二甲胺 、 Cbz-L-苯甘氨酸 在 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以47%的产率得到(S)-(2-(二甲基氨基)-2-氧代-1-苯基乙基)氨基甲酸苄酯
  参考文献：
  名称：

  CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS

  摘要：

  提供了化学式I的羰基氨基吡咯吡唑化合物，包括这些化合物的组合物以及它们的使用方法。化学式I的优选化合物具有作为蛋白激酶抑制剂的活性，包括作为PAK4的抑制剂。

  公开号：

  US20090318440A1

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS
  申请人：Zhang Junhu

  公开号：US20100222342A1

  公开（公告）日：2010-09-02

  Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.

  提供了式I的吡咯吡唑化合物，包括这些化合物的组合物和使用它们的方法。式I的优选化合物具有蛋白激酶抑制剂的活性，包括作为PAK4的抑制剂。
• PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS
  申请人：ZHANG Junhu

  公开号：US20120264751A1

  公开（公告）日：2012-10-18

  Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.

  提供了公式I的吡咯吡唑化合物，包括这些化合物的组合物和使用它们的方法。公式I的优选化合物具有作为蛋白激酶抑制剂的活性，包括作为PAK4抑制剂。
• 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US08030499B2

  公开（公告）日：2011-10-04

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况有效的药物。更具体地说，本发明旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫性疾病、脱发等具有治疗或预防作用的药物。经过密集研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性、良好的脑穿透性和高血浆浓度，从而实现了上述目标。